Cartalax (Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator))
A short synthetic peptide bioregulator from the Khavinson family targeted at cartilage and connective/musculoskeletal tissue. Used in the bioregulator community for joint and cartilage support in short repeated courses.
How it works
As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling.
Key facts
- Molecular weight: ~390 Da
- Half-life: Short (peptide)
- Bioavailability: Oral (encapsulated) or subcutaneous
- Storage: Room temperature (capsules) or refrigerate (injectable).
Dosing overview
- Typical dose: ~1-2 capsules/day or short injectable courses
- Frequency: Once daily
- Duration: 10-30 day courses
- Route: Oral capsule or subcutaneous
Protocol notes
- Taken as short repeatable courses (often 10-30 days), a few times per year.
- Oral encapsulated forms are taken once daily on an empty stomach.
- Often paired with healing peptides in joint-support protocols.
Reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Possible side effects
- Limited Western clinical data
- Injection site reactions (injectable)
- Unknown long-term effects
Research
- Cartilage peptide bioregulators (2015): Reported to support chondrocyte function and cartilage tissue in regional research studies.
Compare Cartalax
Research and educational reference only. Not medical advice.